Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Pulmonary fibrosis due to bleomycin]

J Ranfaing, M Guillier, M L Simon-Rigaud

    Le Poumon Et Le Coeur
    |January 1, 1977
    PubMed
    Summary

    Bleomycin (BLM) is increasingly used with other cancer drugs due to low myelotoxicity. However, pulmonary fibrosis risk necessitates careful patient monitoring and dose limitation to prevent respiratory complications.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Regulation of magnesium ion transport in <i>Escherichia coli</i>: insights into the role of the 5' upstream region in <i>corA</i> expression.

    RNA biology·2024
    Same author

    Optic neuropathy secondary to necrosis of an optic disc melanocytoma: Case report.

    Journal francais d'ophtalmologie·2022
    Same author

    Inhibition of sphingosine 1-phosphate protects mice against chondrocyte catabolism and osteoarthritis.

    Osteoarthritis and cartilage·2021
    Same author

    [A phenomenological approach of treatment-resistant depressions].

    L'Encephale·2013
    Same author

    Febrile hepatitis eosinophilic probable hepatic distomatosis.

    Revue medicale de Nancy·2010
    Same author

    Typhoid and pregnancy.

    Revue medicale de Nancy·2010

    Area of Science:

    • Oncology
    • Pulmonology
    • Pharmacology

    Background:

    • Bleomycin (BLM) is a widely used anti-neoplastic agent, often in combination therapies.
    • Its reduced myelotoxicity makes it a preferred choice, but pulmonary toxicity remains a significant concern.

    Observation:

    • This review synthesizes data from 45 patient cases, including 6 with respiratory insufficiency.
    • Literature review indicates respiratory complications ranging from 2% to 94% depending on assessment criteria.

    Findings:

    • Bleomycin-induced pulmonary fibrosis is a serious risk associated with BLM treatment.
    • Early detection of pulmonary toxicity is crucial, with carbon monoxide (CO) diffusion capacity recommended for monitoring.

    Implications:

    • Close supervision of elderly patients and those with pre-existing respiratory conditions is essential.
    • A maximum cumulative dose of 450 mg of Bleomycin should not be exceeded to mitigate pulmonary risks.

    Related Experiment Videos